

IN THE CLAIMS

Please cancel claims 1-15 and 61-62, amend claims 16, 19, 31, 34, 45, 48, 52, 54, 56, 58, 60, and 63, and add new claims 65-68 as follows:

Claims 1-15 (Cancelled).

16. (Currently Amended) A method of treating [[and/or preventing]] seasonal or perennial allergic rhinitis in a human of 12 years and older which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or an arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL.

17. (Previously Presented) The method of claim 16 wherein the geometric mean steady state maximum plasma concentration (C_{\max}) of desloratadine is produced at a desloratadine geometric mean T_{\max} in the range of about 1.60 to about 2.50 hours.

18. (Previously Presented) The method of claim 16 wherein the arithmetic mean steady state maximum plasma concentration (C_{\max}) of desloratadine is produced at a desloratadine arithmetic mean T_{\max} in the range of about 2.54 to about 3.96 hours.

19. (Currently Amended) A method of treating [[and/or preventing]] seasonal or perennial allergic rhinitis in a human of 12 years and older which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration (C_{\max}) of 3-OH-desloratadine in the range of about 1.50 ng/mL to about 2.34 ng/mL, or an arithmetic mean steady state maximum plasma concentration (C_{\max}) of 3-OH-desloratadine in the range of about 1.60 ng/mL to about 2.50 ng/mL.

20. (Previously Presented) The method of claim 19 wherein the geometric mean steady state maximum plasma concentration (C_{\max}) of 3-OH-desloratadine is produced at a 3-OH-desloratadine geometric mean T_{\max} in the range of about 4.00 to about 6.25 hours.

21. (Cancelled).

22. (Previously Presented) The method of claim 19 wherein the arithmetic mean steady state maximum plasma concentration (C_{\max}) of 3-OH-desloratadine is produced at a 3-OH-desloratadine arithmetic mean T_{\max} in the range of about 3.80 to about 5.95 hours.

23. (Original) The method of claim 19 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.

24. (Original) The method of claim 16 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.

25. (Original) The method of claim 16 wherein the amount of desloratadine is about 5 mg/day.

26. (Cancelled).

27. (Previously Presented) The method of claim 16 wherein a plot of the plasma concentration of desloratadine over time yields a geometric mean AUC(0-24hr) for desloratadine in the range of about 39.5 ng.hr/mL to about 61.8 ng.hr/mL.

28. (Previously Presented) The method of claim 16 wherein a plot of the plasma concentration of desloratadine over time yields an arithmetic mean AUC(0-24hr) for desloratadine in the range of about 45.5 ng.hr/mL to about 71.1 ng.hr/mL.

29. (Previously Presented) The method of claim 19 wherein a plot of the plasma concentration of 3-OH-desloratadine over time yields a geometric mean AUC(0-24hr) for 3-OH-desloratadine in the range of about 24.3 ng.hr/mL to about 38.0 ng.hr/mL.

30. (Previously Presented) The method of claim 19 wherein a plot of the plasma concentration of 3-OH-desloratadine over time yields an arithmetic mean AUC(0-24hr) for 3-OH-desloratadine in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.

31. (Currently Amended) A method of [[treating and/or preventing atopic dermatitis or urticaria]] reducing the severity of pruritus and of hives in a human of 12 years and older with chronic idiopathic urticaria [[in need of such treating and/or preventing]] which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration (C_{max}) of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or an arithmetic mean steady state maximum plasma concentration (C_{max}) of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL.

32. (Previously Presented) The method of claim 31 wherein the geometric mean steady state maximum plasma concentration (C_{max}) of desloratadine is produced at a desloratadine geometric mean T_{max} in the range of about 1.60 to about 2.50 hours.

33. (Previously Presented) The method of claim 31 wherein the arithmetic mean steady state maximum plasma concentration (C_{max}) of desloratadine is produced at a desloratadine arithmetic mean T_{max} in the range of about 2.54 to about 3.96 hours.

34. (Currently Amended) A method of [[treating and/or preventing atopic dermatitis or urticaria]] reducing the severity of pruritus and of hives in a human of 12 years and older with chronic idiopathic urticaria [[in need of such treating and/or preventing]] which comprises administering an effective amount of desloratadine for a

time sufficient to produce a geometric mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine in the range of about 1.50 ng/mL to about 2.34 ng/mL, or an arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine in the range of about 1.6 ng/mL to about 2.50 ng/mL.

35. (Previously Presented) The method of claim 34 wherein the geometric mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine is produced at a 3-OH-desloratadine geometric mean T_{max} in the range of about 4.00 to about 6.25 hours.

36. (Previously Presented) The method of claim 34 wherein the arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine is produced at a 3-OH-desloratadine arithmetic mean T_{max} in the range of about 3.80 to about 5.95 hours.

37. (Original) The method of claim 34 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.

38. (Original) The method of claim 31 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.

39. (Original) The method of claim 31 wherein the amount of desloratadine is about 5 mg/day.

40. (Cancelled).

41. (Previously Presented) The method of claim 31 wherein a plot of the plasma concentration of desloratadine over time yields a geometric mean AUC(0-24hr) for desloratadine in the range of about 39.5 ng.hr/mL to about 61.8 ng.hr/mL.

42. (Previously Presented) The method of claim 31 wherein a plot of the plasma concentration of desloratadine over time yields an arithmetic mean AUC(0-24hr) for desloratadine in the range of about 45.5 ng.hr/mL to about 71.1 ng.hr/mL.

43. (Previously Presented) The method of claim 34 wherein a plot of the plasma concentration of 3-OH-desloratadine over time yields a geometric mean AUC(0-24hr) for 3-OH-desloratadine in the range of about 24.3 ng.hr/mL to about 38.0 ng.hr/mL.

44. (Previously Presented) The method of claim 34 wherein a plot of the plasma concentration of 3-OH-desloratadine over time yields an arithmetic mean AUC(0-24hr) for 3-OH-desloratadine in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.

45. (Currently Amended) A method of treating [[and/or preventing the]] nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and [[for]] of treating symptoms of chronic idiopathic urticaria in a human of 12 years and older [[in need of such treating and /or preventing]] which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce at a desloratadine arithmetic mean time to maximum plasma concentration (T_{max}) of about 3

hours post dose, an arithmetic mean steady state maximum plasma concentration (C_{\max}) of desloratadine of about 4 ng/mL, and an arithmetic mean area under the concentration-time (0-24hr) curve of about 56.9 ng.hr/mL of desloratadine.

46. (Previously Presented) The method of claim 45 wherein the administration of desloratadine produces an arithmetic mean steady state maximum plasma concentration (C_{\max}) of 3-OH-desloratadine, at an arithmetic mean time to maximum plasma concentration (T_{\max}) of 3-OH-desloratadine of about 4.8 hours, of about 2 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of 3-OH-desloratadine of about 32.3 ng.hr/mL.

47. (Cancelled).

48. (Currently Amended) A method of treating [[and/or preventing the]] nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and/or of treating symptoms of chronic idiopathic urticaria in a human of 12 years and older [[in need of such treating and /or preventing]] which comprises administering an effective amount of desloratadine for a time sufficient to produce a steady state geometric mean maximum plasma concentration (C_{\max}) of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL at a geometric mean time to maximum plasma concentration (T_{\max}) of desloratadine in the range of about 1.60 to about 2.50 hours post dose, or a steady state arithmetic mean maximum plasma concentration (C_{\max}) of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL at an arithmetic mean

time to maximum plasma concentration (T_{\max}) of desloratadine in the range of about 2.54 to about 3.96 hours post dose.

49. (Previously Presented) The method of claim 48 wherein the administration of desloratadine produces an arithmetic mean steady state maximum plasma concentration (C_{\max}) of 3-OH-desloratadine, at an arithmetic mean time to maximum plasma concentration (T_{\max}) of 3-OH-desloratadine in the range of about 3.80 hours to 5.95 hours, in the range of about 1.60 ng/mL to about 2.50 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of 3-OH-desloratadine in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.

50. (Cancelled).

51. (Original) The method of claim 48 wherein the amount of desloratadine is about 5 mg/day.

52. (Currently Amended) A method of treating [[and/or preventing the]] nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and/or of treating symptoms of chronic idiopathic urticaria in a human of 12 years and older [[in need of such treating and/or preventing]] which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce an arithmetic mean steady state maximum plasma concentration (C_{\max}) of desloratadine of about 4 ng/mL at an arithmetic mean time to maximum plasma concentration (T_{\max}) of desloratadine of about 3 hours post dose.

53. (Previously Presented) The method of claim 52 wherein the administration of desloratadine produces an arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine, at an arithmetic mean time to maximum plasma concentration (T_{max}) of 3-OH-desloratadine of about 4.8 hours, of about 2.0 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of 3-OH-desloratadine of about 32.3 ng.hr/mL.

54. (Currently Amended) A method of treating [[and/or preventing the]] nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis [[and/or of treating chronic idiopathic urticaria]] in a human of 12 years and older [[in need of such treating and /or preventing]] which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce, at a desloratadine arithmetic mean time to maximum plasma concentration (T_{max}) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration (C_{max}) of desloratadine of about 4 ng/mL, and an arithmetic mean area under the concentration-time (0-24hr) curve of about 56.9 ng.hr/mL of desloratadine.

55. (Previously Presented) The method of claim 54 wherein the administration of desloratadine produces an arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine, at arithmetic mean time to maximum plasma concentration (T_{max}) of 3-OH-desloratadine of about 4.8 hours, of about 2.0 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of 3-OH-desloratadine of about 32.3 ng.hr/mL.

56. (Currently Amended) A method of treating symptoms of chronic idiopathic urticaria in a human of 12 years and older [[in need of such treating and /or preventing]] which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce at a desloratadine arithmetic mean time to maximum plasma concentration (T_{max}) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration (C_{max}) of desloratadine of about 4 ng/mL, and an arithmetic mean area under the concentration-time (0-24hr) curve of about 56.9 ng.hr/mL of desloratadine.

57. (Previously Presented) The method of claim 56 wherein the administration of desloratadine produces an arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine, at arithmetic mean time to maximum plasma concentration (T_{max}) of 3-OH-desloratadine of about 4.80 hours, of about 2.0 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of 3-OH-desloratadine of about 32.3 ng.hr/mL.

58. (Currently Amended) A method of treating [[and/or preventing the]] nasal and non-nasal symptoms of seasonal [[and]] or perennial allergic rhinitis in a human of 12 years and older [[in need of such treating and /or preventing]] which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce, at a desloratadine arithmetic mean time to maximum plasma concentration (T_{max}) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration (C_{max}) of desloratadine of about 4 ng/mL, and an

arithmetic mean area under the concentration-time (0-24hr) curve of about 56.9 ng.hr/mL of desloratadine.

59. (Previously Presented) The method of claim 58 wherein the administration of desloratadine produces an arithmetic mean steady state maximum plasma concentration (C_{\max}) of 3-OH-desloratadine, at arithmetic mean time to maximum plasma concentration (T_{\max}) of 3-OH-desloratadine of about 4.80 hours, of about 2.0 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of 3-OH-desloratadine of about 32.3 ng.hr/mL.

60. (Currently Amended) The method of claim 48 wherein the administration of desloratadine produces a geometric mean steady state maximum plasma concentration (C_{\max}) of 3-OH-desloratadine, at a 3-OH-desloratadine geometric mean time to maximum plasma concentration (T_{\max}) in the range of about 4.00 hours to about 6.25 hours, in the range of about 1.50 ng/mL to about 2.34 ng/mL and a geometric mean area under the concentration-time (0-24hr) curve of 3-OH-desloratadine [[is]] in the range of about 24.3 ng.hr/mL to about 38.0 ng.hr/mL.

Claims 61 and 62 (Cancelled).

63. (Currently Amended) A method of treating [[and/or preventing the]] nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and for treating symptoms of chronic idiopathic urticaria in a human of 12 years and older [[in need of such treating and/or preventing]] which comprises administering to said human

about 5.0 mg of desloratadine once a day for about 7 days to about 10 days to produce, prior to the seventh day after commencement of desloratadine administering,[[,]] an arithmetic mean steady state minimum plasma concentration (C_{min}) of desloratadine of about 1.26 ng/mL and, prior to the tenth day after commencement of desloratadine administering[[]], an arithmetic mean steady state minimum plasma concentration (C_{min}) of desloratadine of about 1.38 ng/mL.

64. (Previously Presented) The method of claim 63 wherein an arithmetic mean steady state minimum plasma concentration (C_{min}) of 3-OH-desloratadine of about 0.792 ng/mL is produced prior to administering a dose on the seventh day after commencement of desloratadine administering, and an arithmetic mean steady state minimum plasma concentration (C_{min}) of 3-OH-desloratadine of about 0.845 ng/mL is produced prior to administering a dose on the tenth day after commencement of desloratadine administering.

65. (New) A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis in a human of 12 years and older which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce, at a desloratadine arithmetic mean time to maximum plasma concentration (T_{max}) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration (C_{max}) of desloratadine of about 4 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of about 56.9 ng.hr/mL of desloratadine.

66. (New) The method of claim 65 wherein the administration of desloratadine produces an arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine, at arithmetic mean time to maximum plasma concentration (T_{max}) of 3-OH-desloratadine of about 4.80 hours, of about 2.0 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of 3-OH-desloratadine of about 32.3 ng.hr/mL.

67. (New) A method of treating nasal and non-nasal symptoms of perennial allergic rhinitis in a human of 12 years and older which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce, at a desloratadine arithmetic mean time to maximum plasma concentration (T_{max}) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration (C_{max}) of desloratadine of about 4 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of about 56.9 ng.hr/mL of desloratadine.

68. (New) The method of claim 67 wherein the administration of desloratadine produces an arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine, at arithmetic mean time to maximum plasma concentration (T_{max}) of 3-OH-desloratadine of about 4.80 hours, of about 2.0 ng/mL and an arithmetic mean area under the concentration-time (0-24hr) curve of 3-OH-desloratadine of about 32.3 ng.hr/mL.